|

PETAL Trial: Impact of Gallium-68 Pentixafor PET-CT on Surgical Outcomes in Primary Aldosteronism

RECRUITINGN/ASponsored by Seoul National University Hospital
Actively Recruiting
PhaseN/A
SponsorSeoul National University Hospital
Started2025-06-25
Est. completion2027-06-01
Eligibility
Age19 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07027254

Summary

This study is a randomized controlled trial to assess the clinical utility of gallium-68 pentixafor PET/CT in the management of primary aldosteronism (PA). We aim to evaluate whether the addition of 68Ga-pentixafor PET/CT to standard adrenal venous sampling (AVS) improves surgical outcomes in patients with unilateral PA.

Eligibility

Age: 19 Years+Healthy volunteers accepted
Inclusion Criteria:

* Age ≥19 years
* Diagnosed with PA per 2016 Endocrine Society guidelines
* Underwent adrenal CT
* Signed informed consent

Exclusion Criteria:

* Women who are pregnant, breastfeeding, or may become pregnant
* Individuals who refuse to undergo surgery
* Individuals for whom 68Ga-Pentixafor PET/CT, 11C-Metomidate PET/CT, or adrenal venous sampling (AVS) is not feasible or is refused due to underlying conditions
* Individuals who refuse or experience adverse effects from dexamethasone premedication required for 11C-Metomidate PET/CT
* Individuals with a history of abdominal open surgery or retroperitoneal surgery on the same side as the planned adrenalectomy
* Any individual deemed unsuitable for the study at the discretion of the investigator

Conditions6

AdrenalectomyAldosterone-Producing AdenomaCancerIdiopathic HyperaldosteronismPrimary AldosteronismSecondary Hypertension

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.